Internship

Process Engineering Intern

Posted on 3/6/2025

ArsenalBio

ArsenalBio

201-500 employees

Develops programmable cell therapies for cancer

Compensation Overview

$25 - $30/hr

Hayward, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Current 3rd or 4th year undergraduate student enrolled in a Bachelors degree program studying Biology, Biochemistry and Molecular Biology, Immunology, or similarly relevant degree program
  • Experience working in a biological laboratory setting with basic lab techniques (e.g. use of PPE, pipetting, centrifuge balancing, lab notebook documentation, aseptic technique) is required
  • Ability to quickly adapt and learn new skills for changing research priorities
  • Flexible mind with the ability to think outside the box, creative approach to problem-solving
  • Demonstrated ability to work well in a highly collaborative team environment, coordinate tasks across multiple projects to meet deadlines
  • Willingness to accept other responsibilities outside of initial job description
Responsibilities
  • Plan, execute, analyze, and report on experiments and analytic assays to support the development, process characterization, and process validation of drug product GMP process to manufacture, characterize, and release T cell therapy products
  • Execute in-process, product, and in-use T cell stability studies using various candidate drug product container configurations to enable various clinical dose levels
  • Execute cryopreservation characterization studies to optimize thermal load distribution and ensure product stability during crucial cryopreservation unit operations
  • Evaluate secondary and tertiary Drug Product container configurations to develop and optimize end-to-end drug product transportation and delivery strategy
  • Collaborate closely with other functions to enable effective and successful project execution
  • Actively engage in cross-functional collaboration with peers
  • Organize, communicate, and present data to key stakeholders
  • Assist cross-functional activities including hand-offs to various teams, compiling data, and presenting at technical meetings
Desired Qualifications
  • Experience with human immune cell isolation, T cell expansion, and mammalian cell culture techniques is desirable
  • Knowledge of cell therapy and/or gene therapy is desirable
  • Experience with data visualization software (e.g. JMP, Prism, Tableau) is a plus
  • Familiarity with/knowledge of biological assays (PCR, Flow Cytometry, Cytokine ELISA) is a plus

Arsenal Biosciences focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Their target clients are patients with solid tumor cancers, a significant segment of the cancer patient population. Arsenal generates revenue through the development and sale of these therapies, aiming to commercialize them once approved. The team consists of experts from various scientific fields and professionals with clinical and manufacturing experience, all working together to create effective cancer treatments.

Company Size

201-500

Company Stage

Series C

Total Funding

$630M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $325 million funding boosts ArsenalBio's clinical development capabilities.
  • Partnerships with Thermo Fisher enhance ArsenalBio's manufacturing and technological capabilities.
  • Growing demand for personalized medicine aligns with ArsenalBio's programmable cell therapy focus.

What critics are saying

  • Emerging competition from companies like Allogene Therapeutics in CAR T-cell therapies.
  • High manufacturing costs may affect ArsenalBio's pricing and market competitiveness.
  • Regulatory scrutiny on gene-editing technologies could delay therapy approvals.

What makes ArsenalBio unique

  • ArsenalBio integrates CRISPR, synthetic biology, and machine learning for advanced cell therapies.
  • Their focus on solid tumors sets them apart in the CAR T-cell therapy space.
  • ArsenalBio's CITE technology enhances T-cell targeting and tumor microenvironment overcoming.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

3%
Arsenal Bio
Jan 6th, 2025
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

Bakersfield.com
Sep 16th, 2024
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.

BioPharma Reporter
Sep 5th, 2024
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies

ArsenalBio bags $325 million to develop crispr-engineered cell therapies.

Arsenal Bio
Sep 4th, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development • Arsenal Bio

Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]

CityBiz
Sep 4th, 2024
T. Rowe Price Joins $325 Million Financing for ArsenalBio

T. Rowe Price joins $325 million financing for ArsenalBio.

INACTIVE